Michael M McNeil1. 1. Immunization Safety Office, Division of Healthcare Quality Promotion, National Center for Zoonotic and Emerging Infectious Diseases, Centers for Disease Control and Prevention, Mailstop V18-4, CDC, 1600 Clifton Rd, Atlanta, GA, 30333, USA.
Abstract
PURPOSE OF REVIEW: Anaphylaxis is a rare, serious hypersensitivity reaction following vaccination, which is rapid in onset and characterized by multisystem involvement. Although anaphylaxis may occur after any vaccine, understanding the risk for this outcome, particularly following influenza vaccines, is important because of the large number of persons vaccinated annually. Recent Findings Two recent CDC safety studies confirmed the rarity of post-vaccination anaphylaxis. In a 25-year review of data from the Vaccine Adverse Event Reporting System (VAERS), reports in children were most common following childhood vaccinations and among adults more often followed influenza vaccine. In a Vaccine Safety Datalink (VSD) study, the estimated incidence of anaphylaxis was 1.3 per million vaccine doses administered for all vaccines and 1.6 per million doses for IIV3 (trivalent) influenza vaccine. SUMMARY: Despite its rarity, its rapid onset (usually within minutes) and potentially lethal nature require that all personnel and facilities providing vaccinations have procedures in place for anaphylaxis management.
PURPOSE OF REVIEW: Anaphylaxis is a rare, serious hypersensitivity reaction following vaccination, which is rapid in onset and characterized by multisystem involvement. Although anaphylaxis may occur after any vaccine, understanding the risk for this outcome, particularly following influenza vaccines, is important because of the large number of persons vaccinated annually. Recent Findings Two recent CDC safety studies confirmed the rarity of post-vaccination anaphylaxis. In a 25-year review of data from the Vaccine Adverse Event Reporting System (VAERS), reports in children were most common following childhood vaccinations and among adults more often followed influenza vaccine. In a Vaccine Safety Datalink (VSD) study, the estimated incidence of anaphylaxis was 1.3 per million vaccine doses administered for all vaccines and 1.6 per million doses for IIV3 (trivalent) influenza vaccine. SUMMARY: Despite its rarity, its rapid onset (usually within minutes) and potentially lethal nature require that all personnel and facilities providing vaccinations have procedures in place for anaphylaxis management.
Authors: Michael M McNeil; Julianne Gee; Eric S Weintraub; Edward A Belongia; Grace M Lee; Jason M Glanz; James D Nordin; Nicola P Klein; Roger Baxter; Allison L Naleway; Lisa A Jackson; Saad B Omer; Steven J Jacobsen; Frank DeStefano Journal: Vaccine Date: 2014-08-06 Impact factor: 3.641
Authors: Michael M McNeil; Eric S Weintraub; Jonathan Duffy; Lakshmi Sukumaran; Steven J Jacobsen; Nicola P Klein; Simon J Hambidge; Grace M Lee; Lisa A Jackson; Stephanie A Irving; Jennifer P King; Elyse O Kharbanda; Robert A Bednarczyk; Frank DeStefano Journal: J Allergy Clin Immunol Date: 2015-10-06 Impact factor: 10.793
Authors: Lennart Nilsson; Knut Brockow; Johan Alm; Victoria Cardona; Jean-Christoph Caubet; Eva Gomes; Maria C Jenmalm; Susanne Lau; Eva Netterlid; Jürgen Schwarze; Aziz Sheikh; Jann Storsaeter; Chrysanthi Skevaki; Ingrid Terreehorst; Giovanna Zanoni Journal: Pediatr Allergy Immunol Date: 2017-10-10 Impact factor: 6.377